Vital stats: PL Thomas' MenaQ7 long-chain vitamin K2
Study claim: Longer-chain menaquinones -7, -8 and -9 are specifically identified as being more suitable for reducing coronary heart disease compared to the shorter-chain menaquinones -4, -5 and -6.
Published: Gast GCM, et al. A high menaquinone reduces the incidence of coronary heart disease in women. Nutr Metab Cardiovasc Dis 2009 Jan 27. In press.
Abstract: Vitamin K-dependent proteins have been demonstrated to inhibit vascular calcification. Data on the effect of vitamin-K intake on coronary heart disease (CHD) risk, however, are scarce. The objective was to examine the relationship between dietary vitamins K1 and K2 intake, and their subtypes, and the incidence of CHD. Researchers used data from the Prospect—EPIC cohort consisting of 16,057 women, enrolled between 1993 and 1997 and aged 49-70 years, who were free of cardiovascular diseases at baseline. Intake of vitamin K and other nutrients was estimated with a food-frequency questionnaire. Multivariate Cox proportional hazards models were used to analyse the data.
After a mean ? SD follow-up of 8.1 ? 1.6 years, researchers identified 480 incident cases of CHD. Mean vitamin K1 intake was 211.7 ? 100.3mcg/day and vitamin K2 intake was 29.1 ? 12.8mcg/day. After adjustment for traditional risk factors and dietary factors, researchers observed an inverse association between vitamin K2 and risk of CHD with a Hazard Ratio (HR) of 0.91 [95 per cent CI 0.85—1.00] per 10mcg/day vitamin-K2 intake. This association was mainly due to vitamin-K2 subtypes MK-7, MK-8 and MK-9. Vitamin-K1 intake was not significantly related to CHD. A high intake of menaquinones, especially MK-7, MK-8 and MK-9, could protect against CHD. However, more research is necessary to define optimal intake levels of vitamin-K for the prevention of CHD.
Potential applications: For bone health as well as heart health, MenaQ7 is suitable for supplements; it is GRAS for dairy products in the US; and in Europe it is registered for all food applications.
More info: +1 973 984 0900 x 215
Vital stats: Sabinsa's Curcumin C3 Complex
Study claim: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.
Published: Dhillon N, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008 Jul 15;14(14):4491-9.
Abstract: Pancreatic cancer is almost always lethal, and the only US FDA-approved therapies for it, gemcitabine and erlotinib, produce objective responses in
Twenty-five patients were enrolled, with 21 evaluable for response. Circulating curcumin was detectable as drug, albeit at low steady-state levels, suggesting poor oral bioavailability. Two patients showed clinical biological activity. One had ongoing stable disease for more than 18 months; one additional patient had a brief, but marked, tumour regression (73 per cent) accompanied by significant increases (4- to 35-fold) in serum cytokine levels( IL-6, IL-8, IL-10, and IL-1 receptor antagonists). No toxicities were observed.
Curcumin down-regulated expression of NF-kappa B, cox-2 and phosphorylated signal transducer and activator of transcription 3 in peripheral blood mononuclear cells from patients — most of whom had baseline levels considerably higher than those found in healthy volunteers. Whereas there was considerable interpatient variation in plasma curcumin levels, drug levels peaked at 22 to 41ng/mL and remained relatively constant over the first four weeks.
Potential applications: Curcumin C3 Complex is an extract of turmeric standardised to 95 per cent curcuminoids. C3 Complex continues to be investigated in the treatment of patients with cancer, neurodegenerative diseases and diseases characterised by chronic inflammatory process.
+1 732 777 1111